ESPR Esperion Therapeutics Inc

Price (delayed)

$3.16

Market cap

$813.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

$0

Enterprise value

$1.2B

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 66

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make ...

Highlights
Esperion Therapeutics's EPS has surged by 100% QoQ and by 100% YoY
The net income has soared by 95% YoY and by 67% from the previous quarter
The quick ratio has grown by 33% YoY but it has contracted by 6% from the previous quarter

Key stats

What are the main financial stats of ESPR

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
0%
1 week
0%
1 month
0.96%
1 year
203.85%
YTD
-14.59%
QTD
15.33%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$418.24M
Gross profit
$285.99M
Operating income
$75.79M
Net income
-$7.42M
Gross margin
68.4%
Net margin
-1.8%
Esperion Therapeutics's net margin has surged by 97% YoY and by 68% QoQ
The net income has soared by 95% YoY and by 67% from the previous quarter
The company's gross profit has surged by 69% YoY and by 4.4% QoQ
ESPR's revenue has surged by 61% year-on-year and by 3.7% since the previous quarter

Price vs fundamentals

How does ESPR's price correlate with its fundamentals

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.9
EV/EBIT
15.13
EV/EBITDA
15.11
EV/Sales
2.87
Esperion Therapeutics's EPS has surged by 100% QoQ and by 100% YoY
The equity has increased by 28% YoY
ESPR's revenue has surged by 61% year-on-year and by 3.7% since the previous quarter
The price to sales (P/S) is 32% lower than the 5-year quarterly average of 2.8 but 27% higher than the last 4 quarters average of 1.5

Efficiency

How efficient is Esperion Therapeutics business performance
The return on invested capital has surged by 190% year-on-year and by 23% since the previous quarter
Esperion Therapeutics's return on sales has surged by 156% YoY and by 20% QoQ
The return on assets has surged by 96% year-on-year and by 70% since the previous quarter

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 40% less than the total liabilities
The total assets has grown by 43% YoY
The quick ratio has grown by 33% YoY but it has contracted by 6% from the previous quarter
The equity has increased by 28% YoY
ESPR's debt to equity is down by 27% year-on-year but it is up by 2.2% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.